Pharmacogenetic biomarkers of response in Crohn’s disease

Teresa Linares-Pineda; Maria Luisa Canadas Garre; Antonio Sanchez-Pozo; Miguel Angel Calleja Hernandez

doi:10.1038/tpj.2017.27

Pharmacogenetic biomarkers of response in Crohn’s disease

Teresa Linares-Pineda
, Maria Luisa Canadas Garre
, Antonio Sanchez-Pozo
, Miguel Angel Calleja Hernandez

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Review article › peer-review

14 Citations (Scopus)

1136 Downloads (Pure)

Abstract

Crohn’s disease (CD) is a chronic condition, which affects the immune system. It can also affect any part of the digestive tract and
be associated with external manifestations. The causes of the disease remain unknown, although it seems to be the result of a
combination of factors, such as genetic predisposition, environment, lifestyle and the composition of the microbiota, among others.
The treatment protocol begins with a change in eating and smoking habits, and is continued with different lines of treatment,
including corticosteroids, immunomodulators and biologic therapy (inﬂiximab and adalimumab), which have shown differences in
response among patients, especially with biologic treatment. Several studies have considered the possibility that these differences
in response are caused by the genetic variability of patients. Many genes have been investigated as potential predictors of response
to biological drugs, such as ADAM17, ATG16L1, EMSY, CASP9, CCNY, CNTN5, FASLG, FCGR, NOD2, PTGER4, IL13, IL1B, IL27, IL11, IL17F,
TNF and TNFR genes. In this review, we will gather the information on inﬂuence of gene polymorphisms investigated to date on
response to biological drugs in CD patients.

Original language	English
Pages (from-to)	1-13
Journal	The pharmacogenomics journal
Early online date	20 Jun 2017
DOIs	https://doi.org/10.1038/tpj.2017.27
Publication status	Early online date - 20 Jun 2017

Access to Document

10.1038/tpj.2017.27Licence: Unspecified

Pharmacogenetic biomarkers of response in Crohn’s disease
Copyright Macmillan Publishers Limited 2017. This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 352 KBLicence: Unspecified

http://rdcu.be/tzxG Licence: Unspecified

Cite this

@article{bd7e8c513d1548b6ae06540e6efe7ec2,

title = "Pharmacogenetic biomarkers of response in Crohn{\textquoteright}s disease",

abstract = "Crohn{\textquoteright}s disease (CD) is a chronic condition, which affects the immune system. It can also affect any part of the digestive tract and be associated with external manifestations. The causes of the disease remain unknown, although it seems to be the result of a combination of factors, such as genetic predisposition, environment, lifestyle and the composition of the microbiota, among others. The treatment protocol begins with a change in eating and smoking habits, and is continued with different lines of treatment, including corticosteroids, immunomodulators and biologic therapy (inﬂiximab and adalimumab), which have shown differences in response among patients, especially with biologic treatment. Several studies have considered the possibility that these differences in response are caused by the genetic variability of patients. Many genes have been investigated as potential predictors of response to biological drugs, such as ADAM17, ATG16L1, EMSY, CASP9, CCNY, CNTN5, FASLG, FCGR, NOD2, PTGER4, IL13, IL1B, IL27, IL11, IL17F, TNF and TNFR genes. In this review, we will gather the information on inﬂuence of gene polymorphisms investigated to date on response to biological drugs in CD patients.",

author = "Teresa Linares-Pineda and \{Canadas Garre\}, \{Maria Luisa\} and Antonio Sanchez-Pozo and \{Calleja Hernandez\}, \{Miguel Angel\}",

year = "2017",

month = jun,

day = "20",

doi = "10.1038/tpj.2017.27",

language = "English",

pages = "1--13",

journal = "The pharmacogenomics journal",

issn = "1470-269X",

publisher = "Springer Nature",

}

TY - JOUR

T1 - Pharmacogenetic biomarkers of response in Crohn’s disease

AU - Linares-Pineda, Teresa

AU - Canadas Garre, Maria Luisa

AU - Sanchez-Pozo, Antonio

AU - Calleja Hernandez, Miguel Angel

PY - 2017/6/20

Y1 - 2017/6/20

N2 - Crohn’s disease (CD) is a chronic condition, which affects the immune system. It can also affect any part of the digestive tract and be associated with external manifestations. The causes of the disease remain unknown, although it seems to be the result of a combination of factors, such as genetic predisposition, environment, lifestyle and the composition of the microbiota, among others. The treatment protocol begins with a change in eating and smoking habits, and is continued with different lines of treatment, including corticosteroids, immunomodulators and biologic therapy (inﬂiximab and adalimumab), which have shown differences in response among patients, especially with biologic treatment. Several studies have considered the possibility that these differences in response are caused by the genetic variability of patients. Many genes have been investigated as potential predictors of response to biological drugs, such as ADAM17, ATG16L1, EMSY, CASP9, CCNY, CNTN5, FASLG, FCGR, NOD2, PTGER4, IL13, IL1B, IL27, IL11, IL17F, TNF and TNFR genes. In this review, we will gather the information on inﬂuence of gene polymorphisms investigated to date on response to biological drugs in CD patients.

AB - Crohn’s disease (CD) is a chronic condition, which affects the immune system. It can also affect any part of the digestive tract and be associated with external manifestations. The causes of the disease remain unknown, although it seems to be the result of a combination of factors, such as genetic predisposition, environment, lifestyle and the composition of the microbiota, among others. The treatment protocol begins with a change in eating and smoking habits, and is continued with different lines of treatment, including corticosteroids, immunomodulators and biologic therapy (inﬂiximab and adalimumab), which have shown differences in response among patients, especially with biologic treatment. Several studies have considered the possibility that these differences in response are caused by the genetic variability of patients. Many genes have been investigated as potential predictors of response to biological drugs, such as ADAM17, ATG16L1, EMSY, CASP9, CCNY, CNTN5, FASLG, FCGR, NOD2, PTGER4, IL13, IL1B, IL27, IL11, IL17F, TNF and TNFR genes. In this review, we will gather the information on inﬂuence of gene polymorphisms investigated to date on response to biological drugs in CD patients.

U2 - 10.1038/tpj.2017.27

DO - 10.1038/tpj.2017.27

M3 - Review article

SN - 1470-269X

SP - 1

EP - 13

JO - The pharmacogenomics journal

JF - The pharmacogenomics journal

ER -

Pharmacogenetic biomarkers of response in Crohn’s disease

Abstract

Access to Document

Fingerprint

Cite this